A study by Shujuan Li and colleagues from the Jilin University, Changchun, China, suggests that Th17 and Th22 cells might be involved in the onset and development of Guillain-Barré Syndrome.
The report by Li et al, published in the journal Mediators of Inflammation, indicates that in the early, acute phase of Guillain-Barré syndrome circulating Th17, Th22 cells and Th1 cells are increased along with the plasma levels of IL-17 and IL-22.
This may also indicate that targeting Th17 and Th22 cells may have therapeutic potential in Guillain-Barré syndrome. In fact, a more recent review published in Expert Opinion on Therapeutic Targets provides a more detailed discussion along these lines.
Source: Mediators Inflamm, 2014:740947. doi: 10.1155/2014/740947. Epub 2014 May 12.
Read More: Mediators of Inflammation